Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer

Clinical Chemistry

Volumn 50, Issue 5, 2004, Pages 826-835

  O'Hara, S Mark ^a   Moreno, Jose G ^b   Zweitzig, Daniel R ^a   Gross, Steve ^a   Gomella, Leonard G ^b   Terstappen, Leon W M M ^a  

^a Immunicon Corporation   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; HORMONE; INTERCELLULAR ADHESION MOLECULE 1; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TISSUE KALLIKREIN;

ARTICLE; BLOOD SAMPLING; CELL ASSAY; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; EVALUATION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOMAGNETIC SEPARATION; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PHENOTYPE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, ANTISENSE; RNA, MESSENGER; TREATMENT FAILURE;

EID: 2142822261     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.028563     Document Type: Article

References (23)

1. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 2000;341:525-33.
2. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001;92:46-53.
3. Halabl S, Small EJ, Hayes DF, Vogelzang HN, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB9583. J Clin Oncol 2003;21: 490-5.
4. Cristofanilli M, Reuben JM, Fritsche HA, Kau SW, Lara J, Arun B, et al. Circulating tumor cells (CTCs): a novel prognostic factor for newly diagnosed metastatic breast cancer (MBC). Proc Am Assoc Cancer Res 2003;44:1349.
5. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003;61:277-81.
6. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
7. Van Gelder RN, von Xastrow ME, Yool A, Dement DC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
8. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003;95:598-605.
9. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002;21: 1111-8.
10. Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001;58:386-92.
11. Kagan M, Howard D, Bendele T, Mayes J, Silvia J, Repollet M, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002;25:104-10.
12. Kagan M, Trainer M, Bendele T, Rao C, Horton A, Tibbe A, et al. CellTracks cell analysis system for rare cell detection. In: Cohn GE, ed. Clinical diagnostic systems: technologies and instrumentation. Washington: SPIE, 2002;4625:20-8.
13. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
14. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997;158:326-37.
15. Moreno JG, Gomella LG. Circulating prostate cancer cells detected by reverse transcription-polymerase chain reaction (RT-PCR): what do they mean? Cancer Control 1998;5:507-12.
16. Ylikoski A, Karp M, Pettersson K, Lilja H, Lovgren T. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients. J Mol Diagn 2001;3:111-22.
17. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000;60:6568-72.
18. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8.
19. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, et al. Expression profiling reveals HPN overexpression in prostate cancer. Cancer Res 2001;61:5692-6.
20. Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;11:3438-44.
21. Willman JH, Holden JA. Immunohistochemical staining for DNA topoisomerase II-α in benign, premalignant, and malignant lesions of the prostate. Prostate 2000;42:280-6.
22. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
23. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 1994;54:6344-7.